Bassem Razzouk
Pediatric Hematology-Oncology · Indianapolis, INNPI 1124021829
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,480 of the $42,483 with a category attached, or 78.8%. Jazz Pharmaceuticals Inc. accounts for 94.3% of it on its own, with 16 other manufacturers making up the rest. Among pediatric hematology-oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $685.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$40K
- Sobi, Inc$458
- Tersera Therapeutics LLC$400
- Amgen$394
- Rigel Pharmaceuticals, Inc.$246
- Incyte Corporation$159
- plus $743 from 11 others
Across 17 payments — averaging $25,894 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$423K
- E.r. Squibb & Sons, L.L.C.$9K
- X4 Pharmaceuticals, Inc.$5K
- Incyte Corporation$3K
What the payments were for
- Consulting fees$4001%
- Speaking & faculty fees$33,48079%
- Travel & lodging$5,67113%
- Food & beverage$2,7707%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 29 | $40,083 |
| Sobi, Inc | 6 | $458 |
| Tersera Therapeutics LLC | 1 | $400 |
| Amgen | 5 | $394 |
| Rigel Pharmaceuticals, Inc. | 3 | $246 |
| Incyte Corporation | 2 | $159 |
| Fennec Pharmaceuticals, Inc. | 3 | $148 |
| Foundation Medicine, Inc. | 1 | $140 |
| Genentech, Inc. | 1 | $127 |
| Seagen Inc. | 2 | $77 |
| AstraZeneca | 1 | $60 |
| Bayer | 2 | $49 |
| RARE Disease Therapeutics, Inc. | 1 | $48 |
| Servier Pharmaceuticals LLC | 2 | $37 |
| Y-mabs Therapeutics, Inc. | 1 | $25 |
| Silvergate Pharmaceuticals, Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYLAZE$39,941
- Blincyto$351
- Gamifant$242
- Tavalisse$222
- FOUNDATIONONE$140
- FOUNDATIONONE HEME$140
- FOUNDATIONONE CDX$140
- FOUNDATIONFOCUS$140
- FOUNDATIONONE LIQUID CDX$140
- JAKAFI$133
- Rezlidhia$121
- Pedmark$117
How this compares
$42,483 in reported general payments places this provider in the 95th percentile of 59 pediatric hematology-oncology providers in Indiana.
See all pediatric hematology-oncology providers in Indiana →
Other pediatric hematology-oncology in Indianapolis
- Amy ShapiroIndianapolis$287K
- Sanjay AhujaIndianapolis$197K
- Melissa BearIndianapolis$26K
- Steven RhodesIndianapolis$13K
- Kyle DavisIndianapolis$10K
- Seethal JacobIndianapolis$8K
- Charles NakarIndianapolis$5K
- Scott CovenIndianapolis$4K
- Sandeep BatraIndianapolis$4K
- Kerry HegeIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.